@article {Yang1408, author = {Zhongyi Yang and Yingjian Zhang}, title = {The clinical value of whole body Fluorine-18 Fluorodeoxyglucose PET/CT for detecting metastatic bladder cancer}, volume = {53}, number = {supplement 1}, pages = {1408--1408}, year = {2012}, publisher = {Society of Nuclear Medicine}, abstract = {1408 Objectives The purpose of our study was to investigate the value of whole body Fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) for detection of metastatic bladder cancer. Methods From December 2006 to August 2010, 60 bladder cancer patients (median age 60.5 years old, ranging from 32~96) underwent PET/CT from the proximal thighs to head. The accuracy of PET/CT was assessed using both organ-based and patient-based analyses. Lesions were validated by either biopsy or clinical follow-up for at least 6 months. Results One hundred and thirty-four suspicious lesions were identified in 60 eligible patients. Among these lesions, 4 secondary primary cancers (2 pancreatic cancers, 1 colonic and 1 nasopharyngeal cancer) were validated incidentally and the patients were treated in time. For the remaining 130 lesions, PET/CT detected 118 true positive lesions (sensitivity=95.9\%). On patient-based analyses, the overall sensitivity and specificity were 87.1\% and 89.7\%, respectively. As for metastasis detection by PET/CT, there was no difference of sensitivity and specificity in patients with or without adjuvant treatment. Compared with conventional imaging modality, PET/CT correctly changed the management in 15 patients (25.0\%). Conclusions PET/CT has excellent sensitivity and specificity in the detection of metastatic bladder cancer and provides additional diagnostic information}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/53/supplement_1/1408}, eprint = {https://jnm.snmjournals.org/content}, journal = {Journal of Nuclear Medicine} }